| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | α-lactalbumin vaccine (Breast Cancer Vaccine) Neoadjuvant setting for breast cancer (planned Phase 2) | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology | |
Phase 2 data readout example | α-lactalbumin vaccine (Breast Cancer Vaccine) Neoadjuvant setting for breast cancer (planned Phase 2) | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology | |
Phase 2 data readout example | α-lactalbumin vaccine (Breast Cancer Vaccine) Neoadjuvant setting for breast cancer (planned Phase 2) | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology |
Recent Updates
Recently added Catalysts
Anixa Biosciences, Inc.$3.42
-0.14 (-3.93%)
D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
85.50 M
EPS
-0.32
P/E Ratio
-8.1 $
Value Trade
227.21 K
SEC Financials
Q2 2026Dilution Risk
25%R&D Expenses
1.26 M
Total Assets
14.87 M
Total Liabilities
1.64 M
Equity
14.47 M
D/E Ratio
12,345
-1.76 %
Week
-5.1 %
1 Month
-3.12 %
3 Month
-36.3 %
6 Month
-33.25 %
5 Year
-84.44 %
All Time
Cash Data
Cash Position
13.69 M
Monthly Burn
882.00 K
Runway
13.9 mo
Burn Trend
StableSEC Filing
Jun 10, 2026
Overview
Volume
178.41 K
52 Week Range
2.44 - 5.46
% held by Insiders
3.56 %
% held by Institutions
14.93 %
Enterprise Value
70.26 M
Total Shares
33.51 M
Short %
3.89 %
Float Shares
22.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Anixa Biosciences, Inc.
386Total events
3Upcoming
48Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 2
TBD
T3Enrollment Update
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲Patent GrantedIP / Competition
Subscribe to view catalyst details
TBD
▲Primary Endpoint MetClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-22 | liraltagene autoleucel (lira-cel) | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-22 | liraltagene autoleucel (lira-cel) | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-22 | liraltagene autoleucel (lira-cel) | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D27
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 31%
Micro Cap (rank 639 of 924)
Percentile RankAnixa Biosciences, Inc. faces pipeline headwinds (27/100), with $46M risk-adjusted pipeline value, led by α-lactalbumin vaccine in Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| α-lactalbumin vaccine Monoclonal antibody | Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer | Phase 1 | NCT04674306 | 9% | $46M | ACTIVE NOT_RECRUITING | 35 | - | - | May 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
breast cancer vaccine | breast cancer | Phase 1 | 2026-06-26 | In the completed Phase 1 trial of Anixa's breast cancer vaccine, protocol-defined immune responses were generated in 74% of participants, meeting all major primary endpoints and demonstrating the vaccine's safety and tolerability at the maximum tolerated dose. Read More | Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Read More | |
breast cancer vaccine | breast cancer | Phase 1 | 2026-06-26 | In the completed Phase 1 trial of Anixa's breast cancer vaccine, protocol-defined immune responses were generated in 74% of participants, meeting all major primary endpoints and demonstrating the vaccine's safety and tolerability at the maximum tolerated dose. Read More | Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Read More | |
breast cancer vaccine | breast cancer | Phase 1 | 2026-06-26 | In the completed Phase 1 trial of Anixa's breast cancer vaccine, protocol-defined immune responses were generated in 74% of participants, meeting all major primary endpoints and demonstrating the vaccine's safety and tolerability at the maximum tolerated dose. Read More | Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANIXAnixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences announced the acceptance of a new patent in Australia for its breast cancer vaccine technology, enhancing its global intellectual property coverage. The patent, licensed from Cleveland Clinic, supports Anixa's innovative approach to cancer prevention. Following positive results from a Phase 1 trial, the company aims to advance its clinical development and commercialization efforts internationally.
Read more →ANIX▼ -6.7%on this news
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences has treated the first patient in the fifth cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting ovarian cancer. This therapy has shown promising results, with five patients surviving over one year, including one patient beyond two years, and no dose-limiting toxicities reported. The trial aims to evaluate safety and preliminary efficacy in a challenging patient population.
Read more →ANIXAnixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences has been granted a composition of matter patent for its breast cancer vaccine in South Korea, valid through 2040. This patent expands Anixa's global intellectual property portfolio, which is crucial for pursuing regulatory approvals and partnerships. The vaccine has shown positive results in clinical trials, generating immune responses in 74% of participants.
Read more →ANIX▲ +6.5%on this news· ran to +20% by day 3shared move
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences presented positive data from its breast cancer vaccine Phase 1 trial and ongoing CAR-T Phase 1 trial at the New York Academy of Sciences' symposium. The breast cancer vaccine met all primary endpoints, with 74% of participants showing immune responses. The CAR-T therapy, lira-cel, also reported encouraging survival observations. These developments underscore Anixa's progress in cancer immunotherapy.
Read more →ANIX▲ +5.5%on this news
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences announced the presentation of two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium. The presentations will cover their ovarian cancer CAR-T therapy, lira-cel, which shows positive survival data, and a breast cancer vaccine that met all primary endpoints in its Phase 1 trial. These presentations underscore Anixa's collaborations with leading cancer research institutions.
Read more →ANIXAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences has received a Notice of Allowance from the Canadian Intellectual Property Office for its ovarian cancer vaccine technology. This patent, licensed from Cleveland Clinic, aims to elicit an immune response targeting the AMHR2 protein. The technology is part of a broader strategy to develop cancer vaccines, complementing existing U.S. patent protections. Anixa's collaboration with Cleveland Clinic and NCI highlights its innovative approach to cancer prevention and treatment.
Read more →ANIXAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences has reported promising survival data from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer. Patients have shown substantial survival beyond the expected median, with one individual living for 28 months. The therapy is being evaluated for safety and efficacy, with no significant adverse effects noted thus far.
Read more →ANIXAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences will feature an interview with CEO Dr. Amit Kumar on Bloomberg TV, discussing the company's advancements in cancer treatment. The segment will highlight the positive results from a Phase 1 trial of their breast cancer vaccine and the encouraging survival data from their ovarian cancer CAR-T therapy. This interview aims to showcase Anixa's innovative approach and business model.
Read more →ANIXAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has announced the issuance of a patent from the Mexican Institute of Industrial Property for its breast cancer vaccine technology, extending patent protection into 2040. This development is part of Anixa's strategy to expand its global patent portfolio, enabling potential partnerships for commercialization. The vaccine has shown positive Phase 1 clinical trial results, demonstrating safety and immune response in patients. Anixa aims to advance to a Phase 2 clinical trial based on these promising findings.
Read more →ANIX▲ +9%on this news
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences announced that Cheryl Cox will present at the ISCT 2026 Annual Meeting about the Phase 1 trial of lira-cel, a CAR-T therapy targeting ovarian cancer. The presentation will cover the trial's design and objectives, showcasing the ongoing positive survival data. The conference will gather global experts in cell and gene therapy.
Read more →ANIXAnixa Biosciences to Participate in RedChip’s Biotech Resurgence: Platforms and Pipelines of Today’s Innovators Conference on April 16, 2026
Anixa Biosciences will participate in the RedChip Biotech Resurgence conference on April 16, 2026. Dr. Amit Kumar will present updates on the company's breast cancer vaccine, which has met primary endpoints in Phase 1 trials, and the ovarian cancer CAR-T therapy lira-cel, which is showing promising survival data. The conference aims to connect investors with biopharma innovators.
Read more →ANIXAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences will participate in the RedChip Biotech Resurgence conference on April 16, 2026. The company's breast cancer vaccine has successfully met its primary endpoints in a Phase 1 trial, with 74% of participants showing immune responses. Additionally, their ovarian cancer CAR-T therapy, lira-cel, is demonstrating positive survival data in an ongoing Phase 1 trial.
Read more →ANIXAnixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences, Inc. announced its participation in the Water Tower Research Insights Conference on April 14, 2026, where CEO Dr. Amit Kumar will present. The company highlighted its successful Phase 1 clinical trial results for its breast cancer vaccine, which achieved primary endpoints, and its ongoing Phase 1 trial for the ovarian cancer CAR-T therapy, lira-cel, which is showing positive survival data. The conference aims to provide investors with insights into Anixa's business strategies and growth outlook.
Read more →ANIXAnixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences' CEO, Dr. Amit Kumar, discussed the company's advancements in cancer immunotherapy during an interview. The breast cancer vaccine has successfully completed a Phase 1 trial, achieving its primary endpoints, while the ovarian cancer CAR-T therapy is showing promising survival data in an ongoing Phase 1 trial. Anixa's innovative approach focuses on collaboration with leading research institutions.
Read more →ANIX▲ +5.4%on this newsshared move
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Anixa Biosciences has announced positive results from its Phase 1 study of a breast cancer vaccine, which met all primary endpoints and demonstrated safety and tolerability. The company is now preparing for a Phase 2 clinical trial, supported by a manufacturing agreement with Cytovance Biologics to produce clinical materials. The vaccine targets a protein associated with breast cancer, aiming to provide therapeutic and preventive benefits.
Read more →ANIXAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences announced that Dr. Robert Wenham will present the status of its Phase 1 clinical trial for lira-cel, a CAR-T therapy for recurrent ovarian cancer, at the Society of Gynecologic Oncology Annual Meeting. The presentation will cover the trial's design and objectives, emphasizing the innovative targeting of the follicle-stimulating hormone receptor. This event is a significant opportunity for networking and sharing advancements in gynecologic oncology.
Read more →ANIXAnixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences' CEO, Dr. Amit Kumar, was featured on the Water Tower Research podcast, discussing positive clinical trial results for their breast cancer vaccine and ovarian cancer CAR-T therapy. He also outlined the company's future plans and financial health. Anixa's collaborations with leading research institutions enhance its innovative cancer treatment portfolio.
Read more →ANIX▲ +6.4%on this newsshared move
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance for a patent from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology. This patent enhances Anixa's global intellectual property coverage and supports its ongoing clinical development efforts. The vaccine has demonstrated promising immune responses in a Phase 1 trial, indicating potential for future commercialization.
Read more →ANIXAnixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences will host its 2026 Annual Meeting on March 10, 2026, featuring a corporate update on its oncology pipeline. The meeting will include a presentation by CEO Dr. Amit Kumar, discussing recent clinical progress, particularly in ovarian and breast cancer treatments. The event is accessible to all interested parties.
Read more →ANIXAnixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Anixa Biosciences announced that Dr. Jose Conejo-Garcia will deliver a keynote speech at the SCTR 2026 Retreat, focusing on the company's Phase 1 clinical trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer. The retreat aims to connect leaders in research and clinical care to advance cell-based therapies. Anixa's innovative approach targets cancer cells while sparing healthy tissue.
Read more →ANIXAnixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Anixa Biosciences reported encouraging results from its Phase 1 CAR-T trial for ovarian cancer, where several patients exceeded expected survival rates. Following a clean safety profile with no dose-limiting toxicities, the company received regulatory approval to escalate doses significantly. The trial aims to enhance efficacy through intra-peritoneal delivery and lymphodepletion.
Read more →ANIXAnixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Anixa Biosciences announced the USAN Council's approval of 'liraltagene autoleucel' as the non-proprietary name for its CAR-T therapy targeting recurrent ovarian cancer. This approval follows international recognition by the WHO and is seen as a crucial step towards commercialization. The company continues its Phase 1 trial in partnership with Moffitt Cancer Center.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance from the Mexican Institute of Industrial Property for a patent related to its breast cancer vaccine technology. This patent enhances Anixa's global intellectual property portfolio, particularly in markets with high rates of late-stage and triple-negative breast cancer. The vaccine aims to improve cancer prevention and treatment strategies.
Read more →ANIX▼ -8.9%on this news
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Anixa Biosciences has successfully transferred the IND for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor. Following positive results from the Phase 1 trial, the company aims to initiate a Phase 2 clinical trial utilizing multiple clinical sites. The vaccine targets a protein associated with breast cancer, potentially offering therapeutic benefits.
Read more →ANIX▼ -25.4%on this newsshared move
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences announced positive results from its Phase 1 trial of an investigational breast cancer vaccine, which met all primary endpoints and demonstrated an immune response in 74% of participants. The vaccine was found to be safe and well tolerated, with no major adverse side effects reported. The company plans to advance the program into Phase 2 development.
Read more →ANIX▼ -6.4%on this news· ran to -30% by day 3shared move
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences will participate in the Water Tower Research Fireside Chat on December 15, 2025. CEO Dr. Amit Kumar will discuss various topics related to the company's innovative cancer treatments. The event is open to all investors, providing an opportunity for engagement and insight into Anixa's ongoing projects.
Read more →ANIXAnixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Anixa Biosciences has received approval from the WHO for the non-proprietary name 'liraltagene autoleucel' for its CAR-T therapy targeting recurrent ovarian cancer. This approval is a crucial step towards commercialization and global recognition of the therapy. The company is currently conducting a Phase 1 trial in collaboration with Moffitt Cancer Center, focusing on safety and clinical activity.
Read more →ANIXAnixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences has announced the issuance of a key U.S. patent for its breast cancer vaccine technology, extending protection into the mid-2040s. This patent covers methods to induce an immune response to the α-lactalbumin protein, which is present in certain breast cancers. The vaccine aims to prevent breast cancer by targeting this protein while sparing normal tissue, addressing a critical unmet need in preventive oncology.
Read more →ANIXAnixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Anixa Biosciences, Inc. announced that Dr. Amit Kumar, Chairman and CEO, will participate in the Water Tower Research Fireside Chat on November 11, 2025. The chat will cover the company's ongoing projects, including the status of its breast cancer vaccine Phase 1 clinical trial. This event is accessible to all investors, supporting company transparency and engagement with stakeholders.
Read more →ANIXAnixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences has executed a data transfer agreement with Cleveland Clinic, marking a crucial step in transferring IND sponsorship for its breast cancer vaccine. Following positive results from the Phase 1 trial, Anixa is set to advance to a Phase 2 trial. The vaccine targets a protein associated with breast cancer, potentially offering therapeutic benefits.
Read more →ANIXAnixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences, a biotechnology company focused on cancer treatment, will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025. Mike Catelani, the President and CFO, will deliver a presentation and engage in one-on-one meetings. The event will feature various companies and is expected to attract over 500 investors.
Read more →ANIXAnixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a new patent from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology, which is expected to enhance its global intellectual property coverage. This patent will protect the technology until 2040 and supports Anixa's ongoing clinical development efforts. The vaccine aims to prevent breast cancer by targeting a specific protein associated with the disease.
Read more →ANIX▲ +22.7%on this news
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
Anixa Biosciences has completed the final patient visit in its breast cancer vaccine clinical trial, a significant milestone in its first-in-human evaluation. The trial, which enrolled 35 women, aims to stimulate the immune system to target breast cancer. Comprehensive data analysis will follow, with results to be presented at the San Antonio Breast Cancer Symposium in December.
Read more →ANIX▲ +5.8%on this news
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
Anixa Biosciences announced that the final results of its Phase 1 clinical trial for a breast cancer vaccine will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial, conducted at Cleveland Clinic, evaluated the safety and immunogenicity of the alpha-lactalbumin vaccine. The findings will inform FDA discussions and advance plans for Phase 2 development.
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
Anixa Biosciences, in collaboration with Moffitt Cancer Center, has completed dosing in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. No dose-limiting toxicities have been reported thus far, indicating a positive safety profile. Early observations show several patients remaining alive beyond expected median survival benchmarks, highlighting the potential efficacy of the treatment. The fifth cohort will commence after a standard safety review, further investigating the therapy's effectiveness as dosage levels increase.
Read more →ANIXAnixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences, Inc. has announced a time change for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which will take place on September 9, 2025. Mike Catelani, President and CFO of Anixa, will present the company's progress and engage in one-on-one meetings at the event. Anixa focuses on the treatment and prevention of cancer, utilizing advanced immunotherapy and vaccine technologies in collaboration with leading research institutions.
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, in New York City. Mike Catelani, President and CFO, will deliver a presentation and engage in one-on-one meetings. Anixa is a clinical-stage biotechnology company specializing in cancer treatment and prevention, leveraging unique technologies and partnerships with leading research institutions.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance from the Chinese National Intellectual Property Administration for a patent covering its breast cancer vaccine technology. This patent, which will provide protection into the 2040s, expands Anixa's global intellectual property portfolio and is a significant step towards the company's international commercialization strategy. The vaccine addresses a critical public health challenge in China, where breast cancer incidence has been on the rise, making it an important innovation for cancer prevention. Anixa plans to leverage this patent to explore global opportunities in highly affected regions.
Read more →ANIXAnixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has treated the second patient in the fourth cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer. This cohort is receiving a significantly increased dose of CAR-positive cells, with no dose-limiting toxicities reported so far. The trial, conducted in collaboration with Moffitt Cancer Center, aims to evaluate safety, determine the maximum tolerated dose, and monitor initial signals of clinical activity as it progresses.
Read more →ANIXAnixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Anixa Biosciences has announced the issuance of U.S. Patent Number 12,384,826 for its CAR-T technology, providing protection until 2045. This patent covers core methods essential to Anixa's approach to treating solid tumors, reinforcing the company's intellectual property portfolio. The technology is currently in trials for recurrent ovarian cancer, indicating a push towards addressing significant challenges in cancer treatment. Anixa's collaboration with Moffitt Cancer Center further enhances their development capabilities in immuno-oncology.
Read more →ANIXAnixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Anixa Biosciences has announced that Dr. Robert Wenham, a leading figure in gynecologic oncology, will present insights on advancements in ovarian cancer therapies, including Anixa's CAR-T therapy, at the upcoming 13th Annual Ovarcoming Cancer Conference. This event aims to contribute to the fight against ovarian cancer by uniting survivors, caregivers, and healthcare professionals. The presentation is scheduled for September 18, 2025, and underscores Anixa's commitment to developing innovative cancer treatments in collaboration with Moffitt Cancer Center.
Read more →ANIX▲ +8.3%on this news
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
Anixa Biosciences has initiated the transfer of its Investigational New Drug (IND) application to support an upcoming Phase 2 breast cancer vaccine trial. This follows positive results from a Phase 1 study, where over 70% of patients exhibited desired immune responses. Anixa has engaged Advyzom to assist with the regulatory process as it moves forward under its own sponsorship. The vaccine focuses on targeting a lactation-associated protein which is present in certain breast cancer cells, potentially providing preventive and therapeutic benefits.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance from the Canadian Intellectual Property Office for its breast cancer vaccine technology. This new patent, exclusively licensed from Cleveland Clinic, enhances Anixa's international intellectual property portfolio and strengthens its strategy for future regulatory and commercial endeavors. The breast cancer vaccine, which targets the protein human α-lactalbumin, aims to prevent tumor formation while maintaining normal tissue integrity. The company is actively developing this technology in tandem with broader cancer vaccine initiatives.
Read more →ANIXAnixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences announced the issuance of a new U.S. patent covering its breast cancer vaccine technology, extending its intellectual property protection into the 2040s. This patent enhances the company's position in preventive oncology by covering innovative methods of immunization involving α-lactalbumin, a protein associated with breast tissue. The vaccine is positioned to address significant unmet medical needs in treating and preventing breast cancer, particularly for at-risk populations. Anixa's CEO emphasized the importance of this patent in solidifying the company's leadership in developing next-generation immunotherapies.
Read more →ANIXAnixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences announced the issuance of U.S. Patent Number 12,357,593 for its ovarian cancer vaccine technology, which will be effective from July 15, 2025. This patent provides critical protection for methods associated with eliciting an immune response targeting the AMHR2 receptor, pivotal in treating and preventing ovarian cancer. Developed in collaboration with esteemed institutions such as Cleveland Clinic and the National Cancer Institute, this vaccine aims to benefit high-risk individuals, including those with BRCA mutations. The patent reinforces Anixa's position in the oncology space, facilitating further program advancements.
Read more →ANIXAnixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has begun dosing patients in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This cohort will receive a dosage of three million CAR-positive cells, significantly higher than earlier doses. The trial, conducted in partnership with Moffitt Cancer Center, aims to evaluate safety and efficacy after observing no dose-limiting toxicities in the previous cohort. Anixa's innovative approach targets cancer cells expressing the follicle-stimulating hormone receptor (FSHR), highlighting its potential in personalized cancer treatment.
Read more →ANIXAnixa Biosciences to Host an Investor Webcast on June 26, 2025
Anixa Biosciences, Inc. will host an investor webcast on June 26, 2025, at 2:00 PM EDT. During the event, Dr. Amit Kumar, the Chairman and CEO, will provide an overview of the company's business strategy and therapeutic portfolio, followed by a Q&A session. Anixa is focusing on cancer treatment and prevention, including innovative therapies developed in collaboration with leading research institutions.
Read more →ANIXAnixa Biosciences
Anixa Biosciences, Inc. announced that its CEO, Dr. Amit Kumar, discussed the company’s promising breast cancer vaccine in an interview with the New York Post, and the vaccine was featured on Fox News. The vaccine aims to train the immune system to recognize and attack cancerous cells by targeting the lactation protein α-lactalbumin, which is expressed in malignant cells. Anixa's innovative approach could potentially change the landscape of breast cancer treatment and prevention.
Read more →ANIX▲ +23.2%on this newsshared move
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
Anixa Biosciences announced that Dr. Robert Wenham will present an e-poster on the Phase 1 clinical trial of their ovarian cancer CAR-T immunotherapy at the ESMO Gynaecological Cancers Congress 2025 in Vienna. This clinical trial focuses on genetically engineered T-cells aimed at the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation highlights Anixa's innovative approach in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy.
Read more →ANIX▲ +12.5%on this newsshared move
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Anixa Biosciences has completed enrollment for its Phase 1 clinical trial of a breast cancer vaccine, developed in collaboration with the Cleveland Clinic. The trial has seen participation from 35 women across different cohorts, including those at high risk for recurrence and those receiving pembrolizumab. Preliminary results indicate that the vaccine is well tolerated, with a significant percentage of participants showing immune responses. The company plans to submit the trial data for presentation at a future major scientific meeting.
Read more →ANIXAnixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
Anixa Biosciences, led by CEO Dr. Amit Kumar, has issued a letter to shareholders outlining significant progress in various clinical programs and detailing key upcoming milestones. The company's CAR-T therapy for ovarian cancer is advancing in its Phase 1 trial, showing early signs of efficacy while its innovative breast cancer vaccine is nearing completion of enrollment for its Phase 1 trial. Anixa reports a solid financial position, allowing operational flexibility as it aims for transformative milestones in cancer treatment through innovation. The company is poised for an impactful second half of 2025 with several critical data readouts and FDA interactions anticipated.
Read more →ANIXAnixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Anixa Biosciences has announced the poster presentation of its ovarian cancer CAR-T clinical trial at the 2025 ASCO Annual Meeting. Dr. Pamela D. Garzone will represent the company, with Dr. Robert Wenham as the lead author on the clinical trial. The presentation focuses on a novel CAR-T therapy designed to target the follicle-stimulating hormone receptor in recurrent ovarian cancer. The event will take place in Chicago from June 2, 2025, as part of the Developmental Therapeutics—Immunotherapy session.
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Anixa Biosciences, Inc. will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York City. Mike Catelani, the company's President and CFO, will deliver a presentation and be available for one-on-one meetings. Anixa focuses on innovative cancer treatments, including CAR-T technology for ovarian cancer and vaccines for breast cancer, in collaboration with leading research institutions.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Anixa Biosciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its CAR-T technology patent. This new patent application will reinforce Anixa's strong intellectual property portfolio and covers essential methods integral to their CAR-T approach, which targets solid tumors. The technology is currently under clinical trial at Moffitt Cancer Center, focusing on treating patients with recurrent ovarian cancer. CEO Dr. Amit Kumar emphasized the importance of this patent for supporting their CAR-T program's future success.
Read more →ANIX▲ +13%on this newsshared move
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has announced that it received a Notice of Allowance from the USPTO for a patent related to its breast cancer vaccine technology. This patent broadens the immunogenic compositions for preventing breast cancer and covers methods for immunization using the human α-lactalbumin protein. CEO Dr. Amit Kumar emphasized the novelty and strength of their intellectual property portfolio, which includes several patents in both domestic and international markets.
Read more →ANIXAnixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Anixa Biosciences, Inc. announced its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference on April 8-9, 2025. The President and CFO, Mike Catelani, will deliver a presentation and hold one-on-one meetings during the event. This conference is aimed at facilitating direct dialogue between innovative companies and investors. Anixa continues to highlight its cancer treatment innovations during this significant healthcare event.
Read more →ANIXAnixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Anixa Biosciences has signed a letter of intent with VERDI Solutions to develop AI-guided personalized and off-the-shelf cancer vaccines. VERDI's innovative approach has already shown safety and efficacy in real-world applications for patients with terminal conditions. This collaboration allows Anixa exclusive negotiation rights for six months to pursue research, development, and commercialization of these vaccines. Additionally, both companies plan to initiate clinical trials in the U.S., leveraging VERDI's promising cloud-computing platform for personalized vaccine design.
Read more →ANIXAnixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Anixa Biosciences has received a Notice of Allowance from the United States Patent and Trademark Office for its ovarian cancer vaccine technology. This patent includes broad claims related to methods for eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2). Collaborating with Cleveland Clinic and the National Cancer Institute, Anixa aims to offer a novel preventative and therapeutic solution for ovarian cancer, particularly for high-risk groups. The development reflects a crucial advancement in their ongoing cancer treatment initiatives.
Read more →ANIXAnixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Anixa Biosciences has announced that CEO Dr. Amit Kumar will present at the 2025 CAGLA NeauxCancer Conference on March 28, 2025. His presentation will highlight the company's advancements in cancer treatment, including updates on CAR-T therapy for solid tumors and novel vaccine initiatives. The conference is a key event for oncology researchers, industry leaders, and medical professionals, focusing on developments in cancer care. Anixa's innovative approach includes collaborations with leading research institutions to enhance its therapeutic portfolio.
Read more →ANIX▼ -7.4%on this news
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Anixa Biosciences, Inc. will host its 2025 Annual Meeting of Stockholders on March 20, 2025, in a virtual format. The meeting will include a corporate update from Chairman and CEO Dr. Amit Kumar, along with a question-and-answer session for all interested parties. Anixa is focused on developing innovative cancer therapies, including immunotherapies and vaccines in partnership with leading research institutions.
Read more →ANIX▼ -9.8%on this news
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
Anixa Biosciences has announced that Dr. Pam Garzone, the Chief Development Officer, will participate as a panelist at the Alliance for Cancer Gene Therapy Summit 2025 in New York City. The summit is scheduled for March 19-20, 2025, and will focus on advancements in cell and gene therapy for various cancers, including discussions on Anixa's CAR-T therapy for ovarian cancer. Dr. Amit Kumar, the CEO of Anixa, expressed pride in the opportunity to contribute insights on the future of gene-based treatments for gynecologic and breast cancers.
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has completed the dosing of its final patient in the third cohort of a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer. The increase in dosage from previous cohorts marks a critical step in evaluating the treatment's safety and effectiveness. With the upcoming fourth cohort expected to further escalate the dosage, the company is also expanding access to the trial through a new protocol amendment. This initiative aims to evaluate the full potential of the CAR-T therapy in treating ovarian cancer more effectively.
Read more →ANIX▼ -6.5%on this newsshared move
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
Anixa Biosciences' CAR-T therapy for ovarian cancer was highlighted in a prominent article by Breaking Cancer News. Developed in collaboration with Moffitt Cancer Center, the therapy aims to target FSHR on ovarian cancer cells, presenting a new treatment avenue for patients with limited options. The clinical trial is led by experts in gynecologic oncology and is exploring the innovative approach's implications for solid tumors. Anixa CEO Amit Kumar expressed pride in the recognition and emphasized the potential transformative impact of their work in targeting challenging cancers.
Read more →ANIXAnixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has announced the approval of a protocol amendment for its ongoing CAR-T therapy clinical trial for ovarian cancer, in collaboration with Moffitt Cancer Center. This amendment allows eligible patients to receive a second dose of the therapy and includes new enrollment criteria for specific ovarian cancer histologies. Dr. Robert Wenham stated that this development enhances their capacity to evaluate the treatment's effectiveness, while CEO Dr. Amit Kumar expressed optimism about improving outcomes for patients. Overall, this marks a significant advancement in the approach to treating ovarian cancer.
Read more →ANIXAnixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview
Anixa Biosciences' Chairman and CEO Dr. Amit Kumar discussed the company's innovative CAR-T cell therapy for ovarian cancer and a breast cancer vaccine during an interview with Alpha Wolf Trading. The CAR-T therapy seeks to address the challenges of treating solid tumors, while the vaccine focuses on preventing triple-negative breast cancer. Anixa's strategic partnerships with leading research institutions allow the company to advance its therapies efficiently, minimizing financial burdens typically faced by biotech firms. The developments in both areas could significantly impact cancer treatment and prevention strategies.
Read more →ANIXAnixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum
Anixa Biosciences, Inc. announced that its President and CFO, Mike Catelani, will present at the 18th Annual European Life Sciences CEO Forum in Zurich, Switzerland, on February 27, 2025. The event will feature discussions on innovative talent and investment trends in life sciences, with Catelani highlighting Anixa’s CAR-T therapy for ovarian cancer and its breast cancer vaccine developed in partnership with Cleveland Clinic. This presentation aims to provide updates on Anixa's pipeline and stimulate engagement with potential partners and investors.
Read more →ANIX▲ +16.6%on this news
Anixa Biosciences CEO Provides Letter to Shareholders
Anixa Biosciences' CEO, Dr. Amit Kumar, provided an optimistic letter to shareholders, highlighting significant achievements and goals for 2025. Notably, the company reported positive Phase 1 data for its breast cancer vaccine across several patient groups and showed advancement in its CAR-T program for ovarian cancer. Anixa maintains a strong financial position with $20 million in cash, allowing it to pursue its ambitious development plans, including further clinical trials and vaccine expansion. The letter underscores the company's commitment to innovating cancer therapies and improving patient outcomes.
Read more →ANIXAnixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
Anixa Biosciences, Inc. will present at the iAccess Alpha Virtual Best Ideas Winter Conference on December 10, 2024. CEO Dr. Amit Kumar is scheduled to speak, and the company will also hold one-on-one meetings with qualified investors on December 11. This participation signifies Anixa's ongoing efforts to engage with investors and showcase its cancer treatment and prevention technologies, including collaborations with leading research institutions.
Read more →ANIXAnixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences has decided to purchase Bitcoin as a treasury reserve asset, a move intended to diversify its treasury holdings and leverage the potential value of digital assets. The company also reiterated its stock buyback program as part of its commitment to enhancing shareholder value. CEO Dr. Amit Kumar expressed confidence in the decision, emphasizing the unexpected success of their clinical trials for cancer vaccines. The management believes that acquiring Bitcoin reflects their strategy for prudent financial management and long-term growth.
Read more →ANIXAnixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has announced the dosing of its first patient in the third cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This cohort involves a tenfold increase in the dosage compared to the initial cohort. The trial, conducted in partnership with Moffitt Cancer Center, has so far shown no dose limiting toxicities. Notably, initial observations indicate efficacy through tumor necrosis and T cell infiltration in one patient from the first cohort.
Read more →ANIXAnixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting Data continues positive trend as
Anixa Biosciences, in collaboration with Cleveland Clinic, presented positive data from a Phase 1 clinical trial of its breast cancer vaccine at the 39th SITC Annual Meeting. The trial demonstrated that the vaccine was safe and well-tolerated among participants and showed immune responses in over 70% of patients. The company plans to initiate a Phase 2 study in 2025 which will evaluate the vaccine in the neoadjuvant setting among newly diagnosed breast cancer patients. This development could pave the way for significant advancements in breast cancer prevention and treatment.
Read more →ANIXAnixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anixa Biosciences has announced the public release of data from the Phase 1 study of its breast cancer vaccine, which will be available on their website during the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 8, 2024. The data presentation will focus on a vaccine targeting the alpha-lactalbumin protein found in certain breast cancers. Initial results presented at a previous symposium indicated that the vaccine showed no safety concerns and provoked immune responses in many patients. The trial is a collaboration with the Cleveland Clinic and is backed by funding from the U.S. Department of Defense.
Read more →ANIXAnixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
Anixa Biosciences, Inc. announced that its Chairman and CEO, Dr. Amit Kumar, will present at the Sidoti Micro-Cap Virtual Conference on November 14, 2024. The presentation will include updates on the company's clinical programs, particularly the breast cancer clinical trial data to be released on November 8, 2024, as well as the CAR-T trial for ovarian cancer. The company reports that both trials are producing results that exceed expectations.
Read more →ANIX▲ +22.2%on this newsshared move
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anixa Biosciences, in collaboration with Cleveland Clinic, will present additional data on its Phase 1 breast cancer vaccine trial at the SITC 39th Annual Meeting. This trial focuses on patients with high-risk operable triple-negative breast cancer and those at high genetic risk. Initial data has shown no safety concerns and positive immune responses, suggesting the vaccine may be a viable preventive treatment. The presentation will occur on November 8, 2024, further contributing to discussions on innovative cancer therapies.
Read more →ANIXAnixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has reported the successful administration of a second dose of its CAR-T therapy to a patient in an ongoing Phase 1 clinical trial for ovarian cancer. Following a positive initial treatment, which exhibited signs of tumor necrosis and T cell infiltration, the trial aims to evaluate the therapy's long-term effectiveness. Collaboration with Moffitt Cancer Center has facilitated this advancement, with encouraging early results suggesting potential benefits for patients with recurrent ovarian cancer. The study continues to explore the safety and efficacy of dosage escalations in additional participants.
Read more →ANIXAnixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
Anixa Biosciences has appointed Suyasha Gupta as Senior Director of Clinical Development, where she will collaborate with the Chief Development Officer on ongoing and future clinical trials including a Phase 1 breast cancer vaccine and CAR-T therapy. Gupta brings extensive experience from her previous role at Genentech, which is expected to enhance Anixa’s oncology programs. The company is advancing its breast cancer vaccine strategy focusing on therapeutic rather than preventive approaches, with confidence in regulatory success and patient accessibility. Initial Phase 1 data appears promising, with plans for further presentations at upcoming conferences.
Read more →ANIXAnixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
Anixa Biosciences has submitted a protocol amendment for its ongoing CAR-T therapy trial for ovarian cancer, allowing a second dose of the treatment for suitable patients. Previously, approval was granted for a single patient to receive an additional dose based on favorable tumor biopsy results. This new amendment will enable all eligible patients to potentially receive another dose without needing individual INDs. The company and its partner Moffitt Cancer Center are optimistic about the potential benefits of increased dosing levels.
Read more →ANIXAnixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Anixa Biosciences has announced a Phase 2 study plan for its breast cancer vaccine, which is set to begin in 2025. The trial aims to assess the vaccine's efficacy when used in conjunction with chemotherapy and Keytruda in neoadjuvant settings. This strategic approach seeks to broaden patient enrollment and expedite regulatory approval. Initial Phase 1 data has shown promise, with no safety concerns reported. The breast cancer therapeutic market is projected to grow significantly, which could benefit Anixa's development plans.
Read more →ANIXAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance
Anixa Biosciences announced that it will present its ovarian cancer CAR-T therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference from September 25-27, 2024. The presentation will focus on a Phase 1 trial involving autologous T cells engineered to target the follicle stimulating hormone receptor in recurrent ovarian cancer. Anixa's CAR-T approach represents a novel treatment strategy developed in partnership with experts in the field. This event highlights Anixa's ongoing commitment to advancing cancer therapies.
Read more →ANIXAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
Anixa Biosciences, Inc. announced that Dr. Jose R. Conejo-Garcia will present its ovarian cancer CAR-T technology at the upcoming Rivkin Center-AACR symposium. The technology, which targets the follicle stimulating hormone receptor using engineered T cells, is being developed in partnership with Moffitt Cancer Center. A Phase 1 clinical trial is ongoing, with promising results indicating safety and tumor necrosis in some patients. This novel approach could significantly change ovarian cancer treatment.
Read more →ANIX▲ +6.3%on this news
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Anixa Biosciences, Inc. announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9th to 11th, 2024. The presentation will be available on-demand for registered attendees and includes options for one-on-one meetings with investors. Anixa is focused on advancing cancer treatment and prevention, showcasing its collaboration with Moffitt Cancer Center and Cleveland Clinic in developing cancer immunotherapies and vaccines.
Read more →ANIXAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting
Anixa Biosciences announced that it will present its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society 2024 Annual Meeting in Dublin. The presentation will detail a Phase I clinical trial of autologous T-cells engineered to target the follicle stimulating hormone receptor in recurrent ovarian cancer. This innovative approach, known as CER-T therapy, showcases Anixa's commitment to advancing cancer treatment through collaborations with prestigious institutions.
Read more →ANIX▼ -7.7%on this news
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
Anixa Biosciences announced that the FDA has approved an individual patient Investigational New Drug Application (IND) for a second dose of their CAR-T therapy for ovarian cancer. This decision follows promising results from a patient in the lowest dose cohort, where a biopsy showed tumor necrosis and immune response. The clinical trial at Moffitt Cancer Center is focused on recurrent ovarian cancer patients who have not responded to standard therapies, indicating potential for future patients with similar conditions. The company remains hopeful about the treatment's effectiveness and further dose escalations.
Read more →ANIXAnixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
Anixa Biosciences has announced that its partner, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent on its novel breast cancer vaccine technology. This patent extends protection to Japan, complementing existing patents in the U.S. and Europe. The vaccine targets 'retired' proteins associated with breast cancer to stimulate an immune response. The technology is currently undergoing a phase one clinical trial, which signifies a step forward in clinical development.
Read more →ANIX▲ +16.2%on this newsshared move
Anixa Biosciences Announces $5 Million Share Repurchase Program
Anixa Biosciences has announced a share repurchase program worth up to $5 million as authorized by its Board of Directors. This initiative is aimed at boosting long-term shareholder value, fueled by the company's belief that its stock is undervalued. The program is set to last for 12 months, with repurchases made at the Board's discretion. Anixa is recognized for its focus on cancer treatment and prevention, partnering with esteemed research institutions to advance its clinical pipeline.
Read more →ANIXAnixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has treated the sixth patient in its Phase 1 clinical trial of a novel CAR-T therapy for ovarian cancer, marking potential progress toward the next dosage cohort. Safety profiles from the first two cohorts have been favorable, and if no adverse effects are reported, enrollment for the third dosage group may begin shortly. This study, conducted in partnership with Moffitt Cancer Center, aims to evaluate both safety and efficacy, with an emphasis on the unique targeting of ovarian cells. The promising intraperitoneal delivery method could also improve treatment effectiveness and reduce side effects compared to traditional methods.
Read more →ANIXAnixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has begun treatment for the fifth patient in its Phase 1 clinical trial of a novel CAR-T therapy targeting ovarian cancer. This trial, conducted in collaboration with Moffitt Cancer Center, involves patients who have not responded to at least two prior treatments. Initial cohorts have confirmed the safety of the therapy, and the trial aims to determine the maximum tolerated dose of engineered T-cells focused on the follicle stimulating hormone receptor, which is exclusively expressed on ovarian cells. The innovative CAR-T approach seeks to address the challenges faced by existing therapies for solid tumors.
Read more →ANIXAnixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines - Company currently
Anixa Biosciences, Inc. has expanded its partnership with Cleveland Clinic to develop additional cancer vaccines. The collaboration aims to leverage a novel scientific mechanism for immunizing against certain cancer types, including ongoing Phase 1 clinical trials for triple negative breast cancer and a pre-clinical ovarian cancer vaccine. The research will explore additional cancer targets, and preliminary data from the breast cancer vaccine program has been promising. The company emphasizes its commitment to developing innovative cancer treatments through collaboration with leading research institutions.
Read more →ANIXAnixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences has announced an expansion of its partnership with Cleveland Clinic to develop new cancer vaccines. The collaboration will include developing vaccines for various types of cancer, building on ongoing work for breast cancer and ovarian cancer. Notably, the Phase 1 clinical trial for triple negative breast cancer is already underway, employing a novel approach targeting specific proteins. Anixa's Chair and CEO, Dr. Amit Kumar, expressed optimism regarding the potential advancements stemming from this partnership.
Read more →ANIXAnixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Anixa Biosciences' CEO Dr. Amit Kumar was featured on the "Target: Cancer Podcast" hosted by Dr. Sanjay Juneja. In the episode, they discussed Anixa's groundbreaking vaccine technology aimed at preventing breast cancer by activating the immune system to target cancer cells. This interview provides a significant platform for Anixa to share its innovative approach to cancer treatment with a large audience. The podcast emphasizes collaboration in cancer research and the potential of new technologies to transform patient care.
Read more →ANIXAnixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
Anixa Biosciences, Inc. announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference scheduled for May 8-9, 2024. At the conference, CEO Dr. Amit Kumar will discuss the company's innovations, including a Phase 1 clinical trial for a breast cancer vaccine that has shown promising results. Anixa is also advancing a CAR-T cell therapy for ovarian cancer, which is currently in a Phase 1 trial. The company emphasizes its financial stability, highlighted by no debt and more than two years of cash reserves.
Read more →ANIXAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Anixa Biosciences has appointed Dr. Sanjay Juneja, a prominent oncologist and media personality, to its Cancer Business Advisory Board. Dr. Juneja's influence in cancer prevention and treatment is expected to assist Anixa in educating the community and advancing its clinical programs. His background, including multiple recognitions and a strong social media presence, positions him well to promote Anixa's innovative cancer vaccines and therapeutics. The board also includes notable figures in oncology, enhancing the company's credibility in the field.
Read more →ANIXAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Anixa Biosciences, Inc. has announced its 2024 Annual Meeting of Stockholders, scheduled for March 21, 2024. The meeting will be held virtually, allowing all interested parties to attend. Following the formal voting portion, CEO Dr. Amit Kumar will provide an update on the company's pipeline, which includes first-in-class therapies for cancer prevention and treatment. Anixa's development strategies involve collaborations with prominent institutions to advance its cancer-focused programs.
Read more →ANIXAnixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Anixa Biosciences, Inc. announced that its CEO, Dr. Amit Kumar, will speak at the 24th Annual World Vaccine Congress on April 4, 2024. He will present positive interim results from a Phase 1 clinical trial of a novel breast cancer vaccine, highlighting promising immune responses in 75% of participants. The vaccine aims to combat triple negative breast cancer and is being developed in collaboration with the Cleveland Clinic, backed by U.S. Department of Defense funding.
Read more →ANIXAnixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has initiated dosing for the fourth patient in its Phase 1 clinical trial of a novel CAR-T therapy for ovarian cancer. This step follows the successful completion of the first cohort, where the therapy demonstrated safety and tolerability. The treatment, which targets the follicle stimulating hormone receptor present in ovarian cells, will assess a higher dose intended to enhance the efficacy of the therapy. The research is being conducted in partnership with Moffitt Cancer Center.
Read more →ANIXAnixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Anixa Biosciences has announced its participation in the 2024 NeauxCancer Conference, scheduled for February 29 to March 2, 2024, in New Orleans. CEO Dr. Amit Kumar will present the company's unique approach to cancer treatment using immunotherapy and will hold investor meetings. The conference aims to connect medical professionals with emerging technologies in oncology, enhancing collaboration and potential investment opportunities.
Read more →ANIXAnixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Anixa Biosciences has announced the grant of a Japanese patent for its ovarian cancer vaccine technology, developed in collaboration with the Cleveland Clinic. This patent expands the company's protection previously established in the U.S. and Europe, enhancing its position in the cancer vaccine market. The technology aims to develop a preemptive vaccine against ovarian cancer, leveraging proteins that regulate ovarian growth and diminish post-menopause. The initiative is supported by the National Cancer Institute's PREVENT Program to further bolster cancer prevention efforts.
Read more →ANIX▲ +9.1%on this news· ran to +24% by day 3
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
Anixa Biosciences, Inc. announced its participation in the Sidoti Micro-Cap Virtual Conference scheduled for January 17-18, 2024. CEO Dr. Amit Kumar will present an overview of the company's clinical programs, which include vaccines aimed at preventing breast cancer and an emerging CAR-T therapy. Positive results from a Phase 1 clinical trial of a breast cancer vaccine will also be discussed. Anixa collaborates with renowned institutions like the Cleveland Clinic to enhance its research initiatives.
Read more →ANIXAnixa Biosciences to Present at Biotech Showcase 2024
Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced its participation in the Biotech Showcase 2024, scheduled for January 8-10 in San Francisco. During the event, Anixa will provide updates on its clinical programs and business overview. Notably, the company is collaborating with respected institutions on developing novel cancer therapies, including immunotherapies targeting ovarian cancer and vaccines designed to prevent triple negative breast cancer. Anixa's management will also be available for one-on-one meetings throughout the event week.
Read more →ANIXAnixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine - Antige
Anixa Biosciences, Inc. has announced positive results from its Phase 1 clinical trial of a breast cancer vaccine, conducted in collaboration with Cleveland Clinic. The trial showed that 75% of participants exhibited antigen-specific T cell responses, and immune biomarkers increased significantly after vaccination. The vaccine was deemed safe with no major side effects reported. Anixa aims to continue with additional cohorts assessing the vaccine's effects alongside Keytruda and further evaluating its impact on individuals with genetic predispositions to breast cancer.
Read more →ANIXAnixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Anixa Biosciences, Inc. plans to hold a conference call this evening to discuss positive new data from its ongoing Phase 1 clinical trial of a breast cancer vaccine. The data will be presented for the first time at the 2023 San Antonio Breast Cancer Symposium. Key opinion leaders in oncology will participate in the call, which aims to provide insights into the vaccine's potential impact on treating triple-negative breast cancer.
Read more →ANIXAnixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Anixa Biosciences announced promising results from their Phase 1 clinical trial of a breast cancer vaccine conducted with Cleveland Clinic. The trial, which focused on patients with triple-negative breast cancer (TNBC), showed that 75% of participants developed antigen-specific immune responses. The vaccine was found to be safe and well tolerated, with significant increases in T cell activation markers over time. Anixa plans to further explore optimal dosing and continue studies in additional patient cohorts.
Read more →ANIXAnixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
Anixa Biosciences, Inc. has announced the receipt of an 'Intention to Grant' notice from the European Patent Office for its ovarian cancer vaccine technology, which is a significant advancement following the recent awarding of a U.S. patent. This European patent aims to extend the protection and commercialization opportunities of the vaccine in larger markets. The technology, developed in collaboration with the Cleveland Clinic, targets a specific receptor in ovarian cancer, with the potential for impactful cancer treatment and prevention. Anixa's strategic partnerships position it well within the competitive biotechnology landscape.
Read more →ANIXAnixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
Anixa Biosciences is set to present its ongoing Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer at the Ovarian Cancer National Conference from November 1-3, 2023. The presentation will be led by Dr. Pamela Garzone, Chief Development Officer, and aims to engage an audience invested in innovative cancer treatments. The conference, organized by the Ovarian Cancer Research Alliance, emphasizes new therapies in the fight against ovarian cancer, reflecting a collaborative approach to cancer research and development.
Read more →ANIXAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, has appointed Dr. Mark A. Goldberg to its Cancer Business Advisory Board. Dr. Goldberg, an accomplished oncologist and biotechnology executive, brings extensive experience, including his roles with the American Cancer Society and other biotechnology companies. His appointment is expected to provide significant clinical and strategic insight into Anixa's operations and growth in the oncology sector.
Read more →ANIXAnixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, in collaboration with Moffitt Cancer Center, has completed the treatment of the first patient cohort in a clinical trial for its CAR-T therapy aimed at ovarian cancer. All three patients treated in the cohort showed no dose-limiting toxicities, paving the way for immediate enrollment in a higher dose cohort. The therapy targets the follicle stimulating hormone receptor, ideally minimizing negative side effects and maximizing efficacy. The trial represents a significant step forward in CAR-T therapies for solid tumors, which have historically faced challenges.
Read more →ANIX▲ +5.6%on this news
Anixa Biosciences Establishes Cancer Business Advisory Board
Anixa Biosciences has formed a Cancer Business Advisory Board (CBAB) to guide its clinical and business development activities. The board is co-chaired by the company's CEO Dr. Amit Kumar and Board Director Dr. Arnold Baskies, and includes renowned experts in oncology and cancer care. This initiative aims to leverage expert guidance and networks to advance Anixa's development of innovative cancer treatments.
Read more →ANIXAnixa Biosciences to Participate in September Investor Conferences
Anixa Biosciences, Inc. will participate in two investor conferences in September, including the H.C. Wainwright 25th Annual Global Investment Conference and the 2023 Cantor Global Healthcare Conference. During these events, Anixa will present its cancer treatment and prevention initiatives, including its ovarian cancer immunotherapy program and novel breast cancer vaccine. Management will also hold one-on-one meetings with investors, demonstrating its commitment to engaging with stakeholders. The presentations will be available online for registered attendees.
Read more →ANIXAnixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has commenced treatment of the third patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer, conducted in collaboration with Moffitt Cancer Center. The trial aims to evaluate safety and effectiveness of the therapy, which targets the follicle stimulating hormone receptor (FSHR) exclusively found in ovarian cells. Assuming the third patient's treatment validates safety, Anixa intends to advance to a higher dosage for the next treatment cohort later this year. Despite slow patient enrollment, the trial's progress suggests potential advancements in ovarian cancer treatment methodologies.
Read more →ANIXAnixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit
Anixa Biosciences has announced that Dr. Pamela D. Garzone will present at the 8th Annual CAR-TCR Summit in Boston, discussing the development of a CAR-T therapy for ovarian cancer. This presentation will address the opportunities and challenges surrounding CAR-T for solid tumors, including details on an ongoing Phase I clinical trial at Moffitt Cancer Center. Additionally, Dr. Garzone will lead a roundtable focusing on CAR-T efficacy and lymphodepletion regimens. The summit provides a platform for global cell therapy leaders to share insights and advancements in the field.
Read more →ANIXAnixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Anixa Biosciences has announced the opening of enrollment for a new treatment arm in its ongoing clinical trial assessing the combination of its breast cancer vaccine and Merck's Keytruda. Conducted in partnership with Cleveland Clinic, this Phase 1 trial will evaluate if the combination enhances the immune response in patients at high risk for triple negative breast cancer. The development is supported by funding from the U.S. Department of Defense, and findings from the trial are anticipated to be presented at the San Antonio Breast Cancer Symposium in December.
Read more →ANIXAnixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
Anixa Biosciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its ovarian cancer vaccine technology, which is being developed in collaboration with Cleveland Clinic. This patent covers a nucleic acid-based delivery system for the vaccine, targeting the anti-Müllerian hormone receptor 2, which is present in ovarian cancers. The company is currently advancing preclinical work supported by the PREVENT Program at the National Cancer Institute, with hopes of further developing this and other innovative cancer prevention strategies.
Read more →ANIX▲ +7%on this news· ran to +22% by day 3
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
Anixa Biosciences has announced the issuance of a Canadian patent for its CAR-T cancer therapy technology, which is currently being evaluated in a Phase 1 clinical trial for ovarian cancer. The patent, covering methods and compositions for treating cancer, was developed in collaboration with The Wistar Institute and involves a novel chimeric antigen receptor targeting specific hormone receptors. CEO Amit Kumar expressed optimism about the technology's potential to target other solid tumors and emphasized its significance in cancer treatment.
Read more →ANIXAnixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has announced the treatment of its second patient in a Phase 1 clinical trial for ovarian cancer using a novel chimeric antigen receptor T-cell (CAR-T) therapy, developed in collaboration with Moffitt Cancer Center. The trial aims to evaluate the safety and activity of this treatment targeting the follicle stimulating hormone receptor, uniquely expressed on ovarian cells. With the completion of this second treatment, the company expresses optimism for patient recruitment and the therapy's potential impact on patients who have exhausted other treatment options.
Read more →ANIX▼ -24.5%on this news
Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine Immune respon
Anixa Biosciences, in partnership with Cleveland Clinic, presented encouraging data from their Phase 1 study of a vaccine targeting triple-negative breast cancer. The study demonstrated immune responses in vaccinated women, who were at high risk for cancer recurrence. The vaccine leverages a protein specific to breast cancer cells, potentially providing preemptive immune protection. However, the trial did not assess whether these immune responses were sufficient to prevent tumor formation.
Read more →ANIX▼ -24.5%on this news
Anixa Biosciences Clarifies Poster Presentation on Company Website
Anixa Biosciences announced a technical error by its website hosting provider that resulted in an unrelated poster presentation appearing on its Corporate Presentations page. The company clarified that the correct presentation of its breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting is available on the Events page of its website. Anixa specializes in cancer treatment and prevention, and is collaborating with reputed institutions for its vaccine development programs.
Read more →ANIX▼ -24.5%on this news
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
Anixa Biosciences, Inc. announced positive data from a Phase 1 trial of its breast cancer vaccine presented by Cleveland Clinic. The trial, which targets triple negative breast cancer patients, observed varying levels of antigen-specific T cell responses at all dose levels tested. Although the immunological responses are promising, the trial's primary goal is not to ascertain the prevention of recurrence, and further studies will evaluate the efficacy of the immune responses.
Read more →ANIX▲ +6.2%on this news
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
Anixa Biosciences, Inc. has announced it will present results from its Phase 1a breast cancer vaccine trial at the 2023 AACR Annual Meeting. Scheduled for April 17, the presentation will focus on its vaccine targeting the lactation protein alpha-lactalbumin, which may help stimulate the immune system against triple-negative breast cancer. This vaccine technology is licensed from Cleveland Clinic, showcasing Anixa's collaboration with leading research institutions to innovate cancer therapies.
Read more →ANIXAnixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
Anixa Biosciences, Inc. announced that it does not hold any accounts at the collapsed Silicon Valley Bank, providing reassurance to its shareholders. The biotechnology company is focused on cancer treatment, with ongoing projects like a CAR-T technology for ovarian cancer and vaccines for breast and ovarian cancer. Anixa's approach involves collaboration with prestigious institutions to develop and commercialize its therapeutic innovations.
Read more →ANIXAnixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
Anixa Biosciences, Inc. will provide a corporate update during its 2023 Annual Meeting of Stockholders on March 9, 2023. CEO Dr. Amit Kumar will present the company's business model and various program updates, followed by a question-and-answer session. The meeting is accessible to shareholders and interested parties through a virtual platform. Anixa is focused on innovative cancer treatments and preventive vaccines, notably in partnership with major research institutions.
Read more →ANIX▲ +7.9%on this news· ran to +20% by day 3shared move
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
Anixa Biosciences announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its breast cancer vaccine technology. This additional patent protection expands on the formulation intellectual property initially developed at Cleveland Clinic. The vaccine aims to prevent Triple Negative Breast Cancer, the most aggressive subtype of breast cancer, through an immune response targeting a specific protein. Anixa is conducting clinical trials and expects to present results at the upcoming annual meeting of the American Association for Cancer Research.
Read more →ANIX▼ -5%on this news
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
Anixa Biosciences has announced the establishment of a Breast Cancer Clinical Advisory Board, comprised of leading experts in breast cancer research and clinical development. This move aims to support the company's efforts in advancing its breast cancer vaccine, which is currently in Phase 1 trials. The advisory board's members possess extensive experience in oncology, which will help Anixa in planning and preparing for future clinical trials. This represents a strategic milestone for Anixa as it seeks to innovate in breast cancer treatment and prevention.
Read more →ANIXAnixa Biosciences to Present at Biotech Showcase 2023
SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-pe
Read more →ANIX▼ -5.5%on this news
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its
Read more →ANIXAnixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
SAN JOSE, Calif., Nov. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its ongoing breast cancer vaccine trial
Read more →ANIXDr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences
SAN JOSE, Calif., Oct. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Gar
Read more →ANIX▲ +10.5%on this newsshared move
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
SAN JOSE, Calif., Oct. 26, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine
Read more →ANIXAnixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Societ
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SAN JOSE, Calif., Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Glob
Read more →ANIX▲ +12.1%on this news
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
SAN JOSE, Calif., Aug. 15, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, in conjunction with its partner Moffitt Cancer Center, it has
Read more →ANIX▲ +8.4%on this news
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
SAN JOSE, Calif., July 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Noti
Read more →ANIXAnixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., June 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experiment
Read more →ANIX▼ -9.3%on this news
Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference
SAN JOSE, Calif., May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment
Read more →ANIXAnixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
SAN JOSE, Calif., April 28, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at th
Read more →ANIXAnixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
SAN JOSE, Calif., March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen rece
Read more →ANIX▲ +6.2%on this news
Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC
SAN JOSE, Calif., March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the Company will present at the 2022 Virtual Growth Conference, hosted
Read more →ANIXAnixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to
Read more →ANIXAnixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have
Read more →ANIXAnixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
SAN JOSE, Calif., Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Company is participating in the LifeSci Partners 11th Annual Corpora
Read more →ANIXAnixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant
SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the results of a genomic variant analysis done with its
Read more →ANIX▲ +6.8%on this news
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
SAN JOSE, Calif. and CLEVELAND, Oct. 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that, in conjunction with its partner, Cleveland Clini
Read more →ANIXAnixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology
SAN JOSE, Calif., Oct. 6, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the China National Intellectual Property Administration (CNIPA)
Read more →ANIXAnixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notic
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the vir
Read more →ANIXAnixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer. Dr
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigatio
Read more →ANIX▲ +6.8%on this newsshared move
Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO
SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Director, Dr. Arnold Baskies has been appointed to the World Health Orga
Read more →ANIX▲ +8.9%on this newsshared move
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., Aug. 18, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent fo
Read more →ANIXAnixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the Nation
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application
SAN JOSE, Calif., May 20, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details of th
Read more →ANIXOntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechn
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy
SAN JOSE, Calif., April 19, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has requested additional
Read more →ANIXAnixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
SAN JOSE, Calif., April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress t
Read more →ANIXAnixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed t
Read more →ANIXAnixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has entered into an underwriting agreemen
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its ovarian cancer CA
Read more →ANIXAnixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European
Read more →ANIXAnixa Biosciences to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
SAN JOSE, Calif., March 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Anixa's Chief Executive Officer, Dr. Amit Kumar, has been invited to pre
Read more →ANIXAnixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy
SAN JOSE, Calif., March 4, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued the first European patent for Anix
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference
SAN JOSE, Calif., Feb. 25, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the vir
Read more →ANIXAnixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
SAN JOSE, Calif., Feb. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that animal testing has commenced with two proprietary compounds that have sh
Read more →ANIXAnixa Biosciences to Present at the B. Riley Oncology Investor Conference
SAN JOSE, Calif., Jan. 13, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at B. Rile
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virt
Read more →ANIXAnixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine
SAN JOSE, Calif., Dec. 21, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigatio
Read more →ANIXAnixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently di
Read more →ANIXAnixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., Dec. 1, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Cleveland Clinic for exclusi
Read more →ANIXAnixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine
SAN JOSE, Calif., Nov. 23, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breas
Read more →ANIXAnixa Biosciences to Host Conference Call to Provide Update on Programs
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:3
Read more →ANIXAnixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the vir
Read more →ANIXAnixa and OntoChem Announce Identification of Additional Covid-19 Compounds
SAN JOSE, Calif., Aug. 13, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional candidates through th
Read more →ANIXAnixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission
SAN JOSE, Calif., July 28, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its prophylactic breast cancer vaccine is making progress towards clinic
Read more →ANIXAnixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19
Read more →ANIXAnixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds
SAN JOSE, Calif., July 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have completed the initial in silico screening pr
Read more →ANIXAnixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Exp
Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio SAN JOSE, Calif., July 2, 20
Read more →ANIXAnixa Biosciences and OntoChem Have Synthesized Four Potential Covid-19 Drugs for Testing in Biological Assays
SAN JOSE, Calif., June 1, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthes
Read more →ANIXAnixa Biosciences and OntoChem Announce Discovery of First Covid-19 Therapeutic Candidate
SAN JOSE, Calif., May 4, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that it, with partner OntoChem GmbH, has identified its first thera
Read more →ANIXAnixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Biomarker Insights Highlighting Cchek™ Liquid Biopsy Technology
SAN JOSE, Calif., April 23, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Biomarker
Read more →ANIXAnixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics
SAN JOSE, Calif., April 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that it has entered into a strategic collaboration with OntoChem
Read more →ANIXAnixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference
SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data related to Anixa's recently launched Cchek™ Prostate Cancer Confir
Read more →ANIXAnixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program
SAN JOSE, Calif., Feb. 12, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Departme
Read more →ANIXAnixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference
SAN JOSE, Calif., Jan. 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from studies utilizing Cchek™, the company's artificial intelligenc
Read more →ANIXAnixa Biosciences to Present at Biotech Showcase 2020
SAN JOSE, Calif., Dec. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that its chief executive officer, Dr. Amit Kumar, will present at the Biotec
Read more →ANIXAnixa Biosciences Announces Commercial Launch of Cchek™ Prostate Cancer Confirmatory Test
SAN JOSE, Calif., Dec. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek
Read more →ANIXAnixa Biosciences Provides Update on CAR-T Program
SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced an update regarding the chimeric antigen receptor T-cell (CAR-T) technology
Read more →ANIXAnixa Biosciences to Host Conference Call to Discuss Plans for 2020
SAN JOSE, Calif., Dec. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that it will hold a conference call on December 17, 2019 at 1:30 p.m. Pacifi
Read more →ANIXAnixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium
SAN JOSE, Calif., Dec. 2, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from its ongoing studies utilizing Cchek™, its artificial intellige
Read more →ANIXAnixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Nov. 26, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the addition of Genesis Research, LLC to the ongoing Cchek™ prostate cancer
Read more →ANIXAnixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early pr
Read more →ANIXAnixa Biosciences Announces Collaboration with Idaho Urologic Institute on Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Nov. 20, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced its collaboration with Idaho Urologic Institute, PA (IUI) in the Cchek™ earl
Read more →ANIXAnixa Biosciences Announces Presentation at Cell Symposia: Hallmarks of Cancer
SAN JOSE, Calif., Nov. 7, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from its ongoing studies utilizing Cchek™, its artificial intellige
Read more →ANIXAnixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine
SAN JOSE, Calif., Nov. 5, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued US Pate
Read more →ANIXAnixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
SAN JOSE, Calif., Oct. 28, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the appointment of Emanuele Ostuni, Ph.D. to its Scientific Advisory Board.
Read more →ANIXAnixa Biosciences Announces Collaboration with Urology San Antonio on Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Oct. 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced its collaboration with Urology San Antonio, PA in Anixa's ongoing Cchek™ pro
Read more →ANIXAnixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)
SAN JOSE, Calif., Oct. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the acceptance of an abstract at the 34th Annual Meeting of the Society for Immunotherap
Read more →ANIXAnixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts
SAN JOSE, Calif., Oct. 15, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President,
Read more →ANIXAnixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board
SAN JOSE, Calif., Oct. 10, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the appointment of Ian H. Frazer, MD, AC, FRS, FAA, to its Scientific Advisory Board. D
Read more →ANIXAnixa Biosciences Announces University of Maryland School of Medicine to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Sept. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Marylan
Read more →ANIXAnixa Biosciences Commences Collaboration with Potomac Urology Center on Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Sept. 19, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Potomac Urology Center, PC ("PUC") has joined its Cchek™ early cancer detection st
Read more →ANIXAnixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree
SAN JOSE, Calif., Sept. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, congratulates H. Michael Shepard, Ph.D., a member of Anixa's Scientific Advisory Board, as a recipient
Read more →ANIXIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE THOMAS S. HOWLAND, JR., derivatively on behalf of ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Plaintiff, v. AMIT KUMAR, LEWIS H. TITTERTON, JR., ARNOLD M. BASKIES,
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE THOMAS S. HOWLAND, JR., derivatively on behalf of ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Plaintiff, v. AMIT KUMAR, LEWIS H. TITTERTON, JR., ARNOLD M. BASKIES, JOHN MONAHAN, MICHAEL J. CATELANI, C.A. No.: 2018-0804-K
Read more →ANIXAnixa Biosciences to Present at Two Upcoming Investor Conferences
SAN JOSE, Calif., Aug. 26, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced its participation at two upcoming investor conferences in New York City. Management wil
Read more →ANIXAnixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif., July 29, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that the VA North Texas Health Care System and its non-profit affiliate, the Dallas VA R
Read more →ANIXAnixa Biosciences Announces Additional Patent Issued on Cancer Detection Technology
SAN JOSE, Calif., July 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,3
Read more →ANIXAnixa Biosciences Announces U.S. Department of Veterans Affairs VA Maryland Health Care System Joins Cchek™ Prostate Cancer Study
SAN JOSE, Calif., July 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it is partnering with the VA Maryland Health Care System's Baltimore VA Medical Cen
Read more →ANIXAnixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it has established a strategic alliance and license agreement with Cleveland Clinic
Read more →ANIXAnixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived Suppressor Cells
SAN JOSE, Calif., July 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced it will make available reprints of a recent study in the Journal of Experimental Medicin
Read more →ANIXAnixa Biosciences to Present at the CYTO 2019 - 34th Congress of the International Society for Advancement of Cytometry
SAN JOSE, Calif., May 29, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present updated data from its study utilizing Cchek™, its artificial intelligence
Read more →ANIXAnixa Biosciences to Present at the Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum
SAN JOSE, Calif., May 21, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it will be presenting at the Sachs Associates 5th Annual Immuno-Oncology BD&L and In
Read more →ANIXAnixa Biosciences Announces Completion of Cchek™ Analytical Verification at CLIA Laboratory
SAN JOSE, Calif., May 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test successfully passed all re
Read more →ANIXAnixa Biosciences to Present at B. Riley FBR Institutional Investor Conference
SAN JOSE, Calif., May 2, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference to
Read more →ANIXUS Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259
Read more →ANIXAnixa Biosciences Extends and Expands its Collaboration with New Jersey Urology
SAN JOSE, Calif., April 11, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has extended and expanded its collaboration with New Jersey Urology, LLC ("NJU"). Pu
Read more →ANIXAnixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting
SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study on prostate cancer detection, utilizing Cchek™, its artifici
Read more →ANIXAnixa Biosciences CEO to Present at the New York Academy of Sciences Symposium on Cancer Immunotherapy
SAN JOSE, Calif., March 27, 2019 /PRNewswire/ -- Dr. Amit Kumar, CEO of Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, will participate in a panel presentation discussing the latest science in immunothera
Read more →ANIXU.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate Cancer Study
SAN JOSE, Calif., March 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the Hunter Holmes McGuire VA Medical Center (VAMC) located in Richmond, VA has joined i
Read more →ANIXAnixa Biosciences Announces Notice of Allowance for Additional Cancer Detection Technology Patent
SAN JOSE, Calif., March 14, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowanc
Read more →ANIXAnixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference
SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present its Cchek™ artificial intelligence (AI) based liquid biopsy for the earl
Read more →ANIXAnixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting
SAN JOSE, Calif., Feb. 28, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data in an oral minisymposium presentation from its study utilizing Anix
Read more →ANIXAnixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek™ Prostate Cancer Confirmation Test
SAN JOSE, Calif., Feb. 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has entered into a strategic alliance with ResearchDx to launch its Cchek™ Prostate C
Read more →ANIXAnixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.
SAN JOSE, Calif., and PHILADELPHIA, Feb. 21, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced it has extended its collaboration with The Wistar Institute and Dmitry I. G
Read more →ANIXAnixa Biosciences to Present at Moffitt Cancer Center
SAN JOSE, Calif., Feb. 13, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffi
Read more →ANIXAnixa Biosciences Conference Call Recording Available on Company Website
Anixa Biosciences Conference Call Recording Available on Company Website SAN JOSE, Calif., January 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body s immune system to fight cancer, today announced that it has made
Read more →ANIXAnixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance
SAN JOSE, Calif., Jan. 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the first pate
Read more →ANIXAnixa Biosciences to Hold Conference Call to Discuss Outlook for 2019
SAN JOSE, Calif., Jan. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will hold a conference call on January 24, 2019 at 1:30 p.m. Pacific / 4:30 p.m. East
Read more →ANIXAnixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test
SAN JOSE, Calif., Dec. 19, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it completed a Pre-Submission (Pre-Sub) meeting with the US FDA on December 17, 2018. T
Read more →ANIXAnixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference
SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek
Read more →ANIXAnixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy
SAN JOSE, Calif., Nov. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's
Read more →ANIXAnixa Biosciences Presents Positive Data from its Artificial Intelligence Powered Liquid Biopsy for Prostate Cancer at SITC Conference
SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that its two presentations at the 33rd Annual Meeting of The Society for Immunotherapy of Can
Read more →ANIXAnixa Biosciences to Present at SITC Annual Meeting
SAN JOSE, Calif., Oct. 29, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intel
Read more →ANIXAnixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test
SAN JOSE, Calif., Oct. 24, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that a Pre-Submission (Pre-Sub) meeting with the US FDA has been scheduled on Monday, Decembe
Read more →ANIXMoffitt Cancer Center and Anixa Biosciences Announce Completion of Pre-IND Meeting with FDA for CAR-T Therapy
SAN JOSE, Calif., Oct. 22, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it, along with its partner Moffitt Cancer Center (MCC), completed a pre-IND (Investigati
Read more →ANIXAnixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference
SAN JOSE, Calif., Oct. 17, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the results from its ongoing study utilizing Cchek™, its artificial intelligence (AI) driven early
Read more →ANIXAnixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek™ Artificial Intelligence based Cancer Detection Technology
SAN JOSE, Calif., Oct. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced it has filed an IVD pre-submission with the US Food and Drug Administration (FDA) for use of
Read more →ANIXAnixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board
SAN JOSE, Calif., Oct. 11, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has added to its Scientific Advisory Board, Jose Conejo-Garcia, MD PhD; Marco Davila,
Read more →ANIXAnixa Biosciences to Present at Artificial Intelligence Conference
SAN JOSE, Calif., Oct. 5, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies utilizing Cchek™, Anixa's artificial intell
Read more →ANIXITUS Corporation Forms Alliance with Serametrix Corporation
ITUS Corporation Forms Alliance with Serametrix Corporation SAN JOSE, CA March 5, 2018: ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek , ITUS s proprietary, AI-driven liquid biopsy cancer
Read more →ANIXITUS Receives Notice of NASDAQ Continued Listing Compliance
ITUS Receives Notice of NASDAQ Continued Listing Compliance SAN JOSE, CA October 3, 2017: ITUS Corporation (NASDAQ: ITUS) today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has regained complia
Read more →ANIXITUS Announces Closing of Rights Offering
ITUS Announces Closing of Rights Offering LOS ANGELES, CA April 4, 2017: ITUS Corporation ( ITUS ) (NASDAQ: ITUS), announced that its rights offering of common shares closed today, raising gross proceeds of approximately $4.7 million before payment of dealer manager fee and othe
Read more →ANIXITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering
ITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering LOS ANGELES, CA February 10, 2017: ITUS Corporation ( ITUS ) (NASDAQ: ITUS), a company using the power of the immune system for early cancer detection, is changing the Record Date for its current sto
Read more →ANIXITUS Announces Common Stock Rights Offering and Ownership Day
ITUS Announces Common Stock Rights Offering and Ownership Day LOS ANGELES, CA January 19, 2017: ITUS Corporation ( ITUS ) (NASDAQ: ITUS), a company developing Cchek , a cancer diagnostic platform based on the body s immunological response to a malignancy, today announced that it
Read more →ANIXITUS Announces Cchek Preliminary Cancer Patient Efficacy Study Results
ITUS Announces Cchek Preliminary Cancer Patient Efficacy Study Results LOS ANGELES, CA December 7, 2016: ITUS Corporation ( ITUS ) (NASDAQ: ITUS), today announced preliminary results from its Cchek cancer patient efficacy study. Using its most recent protocols and methods for me
Read more →ANIXITUS Announces Uplisting to
ITUS Announces Uplisting to NASDAQ LOS ANGELES, CA July 9, 2015: ITUS Corporation ( ITUS ) (OTCQB: ITUS), today announced that The NASDAQ Stock Market LLC has approved the listing of the Company s stock for trading on The NASDAQ Capital Market. Trading of the Company s securitie
Read more →ANIXITUS Announces Formation of Cancer Diagnostics Subsidiary
ITUS Announces Formation of Cancer Diagnostics Subsidiary LOS ANGELES, CA - June 23, 2015 - ITUS Corporation ("ITUS") OTCQB: ITUS), today announced that it has formed a new subsidiary, Anixa Diagnostics Corporation ("Anixa"), for the purpose of developing and marketing non-invas
Read more →ANIXITUS Settles Lawsuit with AU Optronics MELVILLE, NY January 5, 201 5 : ITUS Corporation ( ITUS ) (OTCQB: ITUS), a company that builds and protects innovation, today announced that it has settled its lawsuit against AU Op
ITUS Settles Lawsuit with AU Optronics MELVILLE, NY January 5, 2015: ITUS Corporation ( ITUS ) (OTCQB: ITUS), a company that builds and protects innovation, today announced that it has settled its lawsuit against AU Optronics Corporation ( AUO ). The settlement includes cash pay
Read more →ANIXITUS Restructures Convertible Debt MELVILLE, NY
ITUS Restructures Convertible Debt MELVILLE, NY September 10, 2014: ITUS Corporation (the Company ) (OTCQB: ITUS), a company that builds and protects innovation, today announced that it has exchanged $3.5 million of its convertible debt owed to Adaptive Capital LLC into shares o
Read more →ANIXITUS and Videocon Enter Into Termination Agreement and Agree to Effectuate Return of ITUS Shares MELVILLE, NY
ITUS and Videocon Enter Into Termination Agreement and Agree to Effectuate Return of ITUS Shares MELVILLE, NY September 3, 2014: ITUS Corporation (OTCQB: ITUS), a company that builds and protects innovation, today announced that its predecessor company, CopyTele, Inc. has agreed
Read more →ANIXCopyTele Changing Company Name and Stock Ticker Symbol to
CopyTele Changing Company Name and Stock Ticker Symbol to ITUS MELVILLE, NY August 27, 2014: CopyTele, Inc. (the Company ) (OTCQB: COPY), a company that protects the rights of inventors through patent monetization and patent assertion, today announced that on September 2, 2014,
Read more →ANIXCopyTele Raises $4 Million in Registered Direct Offering MELVILLE, NY
CopyTele Raises $4 Million in Registered Direct Offering MELVILLE, NY July 15, 2014: CopyTele, Inc. ( CTI ) (OTCQB: COPY), a company that protects the rights of inventors through patent monetization and patent assertion, today announced that it has raised $4 million via a regist
Read more →ANIXCopyTele Announces
CopyTele Announces August 8, 2014 Claims Construction Hearing in Patent Infringement Lawsuits Against Microsoft and Citrix MELVILLE, NY (Marketwired) July 7th, 2014: CopyTele, Inc. ( CTI ) (OTCQB: COPY), a company that protects the rights of inventors through patent monetizatio
Read more →ANIXCopyTele Announces $3.5 Million Financing from Institutional Investor Melville, NY
CopyTele Announces $3.5 Million Financing from Institutional Investor Melville, NY November 12, 2013: CopyTele, Inc. ( CTI ) (OTCQB: COPY), a company specializing in patent monetization and patent assertion, today announced that it has completed a private placement of a $3,500,0
Read more →ANIXCopyTele Acquires Rights To Patent Portfolio Covering Loyalty Programs Melville, NY
CopyTele Acquires Rights To Patent Portfolio Covering Loyalty Programs Melville, NY April 3, 2013: CopyTele, Inc. ( CTI ) (OTCBB: COPY) today announced that its wholly owned subsidiary, CTI Patent Acquisition Corporation, has acquired the rights to a patent portfolio relating to
Read more →ANIXCopyTele Announces Private Placement MELVILLE, NY
CopyTeleAnnounces Private Placement MELVILLE, NY January 25, 2013: CopyTele, Inc.(OTCBB:COPY) announced today that it has completed the private placement of $1,765,000 of 8% convertible debentures, due January 25, 2015 to accredited investors, including our Chief Executive Offic
Read more →ANIXCopyTele Presenting at the 15 th Annual RedChip Fall Small-Cap Conference Melville, NY
CopyTele Presenting at the 15th Annual RedChip Fall Small-Cap Conference Melville, NY - October 2, 2012: CopyTele, Inc. (OTCBB: COPY) today announced that Robert Berman, CopyTele's (CTI) President and CEO, will be making a presentation regarding CTI's patented technologies a
Read more →ANIXCopyTele Adds Experienced Patent Monetization Team and Appoints New CEO Melville, NY
CopyTele Adds Experienced Patent Monetization Team and Appoints New CEO Melville, NY - September 19, 2012: CopyTele, Inc. (OTCBB:COPY) today announced the appointment to CopyTele of three former executives from Acacia Research Corporation (NASDAQ: ACTG), a premier publicly trad
Read more →ANIXCopyTele Appoints Bruce Johnson to the Company's Board of Directors MELVILLE, NY
CopyTele Appoints Bruce Johnson to the Company's Board of Directors MELVILLE, NY - September 4, 2012: CopyTele, Inc. (OTCBB:COPY) is pleased to announce the appointment of Bruce F. Johnson to serve on the Company's Board of Directors. Mr. Johnson, a self-employed commodity tra
Read more →ANIXCopyTele Terminates Denis A. Krusos as Chief Executive Officer; Lewis H. Titterton, Jr. Appointed Interim Chief Executive Officer MELVILLE, NY
CopyTele Terminates Denis A. Krusos as Chief Executive Officer; Lewis H. Titterton, Jr. Appointed Interim Chief Executive Officer MELVILLE, NY - August 22, 2012: CopyTele, Inc. (OTCBB:COPY) announced today that Denis A. Krusos was terminated as chief executive officer of the Co
Read more →ANIXCopyTele Licenses Technology to AUO For E-Paper and Nano Displays MELVILLE, N.Y.--(BUSINESS WIRE)
Licenses Technology to AUO For E-Paper and Nano Displays MELVILLE, N.Y.--(BUSINESS WIRE)--May 31, 2011--CopyTele, Inc. (OTCBB:COPY) announced today that it has entered into two license agreements with AU Optronics Corp. ("AUO") (NYSE:AUO) of Hsinchu, Taiwan to produce and mar
Read more →ANIXCopyTele Announces Private Placement MELVILLE, N.Y.--(BUSINESS WIRE)
CopyTele Announces Private Placement MELVILLE, N.Y.--(BUSINESS WIRE)--February 10, 2011--CopyTele, Inc. (COPY.OB), a company engaged in the development of E-Paper and nanotube color video thin flat display technologies today announced that it has completed the private placement
Read more →ANIXCopyTele Announces Agreement with ZQX Advisors, LLC to Seek Business Opportunities and Licenses for Its E-Paper Technology MELVILLE, N.Y.--(BUSINESS WIRE)
Announces Agreement with ZQX Advisors, LLC to Seek Business Opportunities and Licenses for Its E-Paper MELVILLE, N.Y.--(BUSINESS WIRE)--August 24, 2009--CopyTele, Inc. (OTCBB:COPY) announced today that it has entered into an Engagement Agreement with ZQX Advisors, LLC, a Minn
Read more →ANIXCopyTele, Inc. Announces Annual Meeting of Stockholders MELVILLE, N.Y.
COPYTELE, INC. EXHIBIT 99 CopyTele, Inc. Announces Annual Meeting of Stockholders MELVILLE, N.Y.--Sept. 22, 2004--CopyTele, Inc. (COPY:OTCBB), announced today that its Annual Meeting of Stockholders will be held at the Fox Hollow, Woodbury, New York on Thursday, October 28, 2
Read more →Competitive Position
How ANIX ranks across every disease it competes inCompetitive Position is a premium feature
See how ANIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial